Arhalofenate Beats Allopurinol for Gout Flares

This article originally appeared here.
Share this content:
Arhalofenate Beats Allopurinol for Gout Flares
Arhalofenate Beats Allopurinol for Gout Flares

MONDAY, Aug. 15, 2016 (HealthDay News) -- Arhalofenate (800 mg) is safe and significantly decreases gout flares compared to allopurinol (300 mg), according to a study published online July 27 in Arthritis & Rheumatology.

Jeffrey Poiley, M.D., from Arthritis Associates in Orlando, Fla., and colleagues from the Arhalofenate Flare Study conducted a randomized controlled phase IIb trial in which patients were randomly assigned (2:2:2:2:1) to receive 600 mg of arhalofenate, 800 mg of arhalofenate, 300 mg of allopurinol, 300 mg of allopurinol plus 0.6 mg of colchicine, or placebo once a day. To qualify, patients (239) had had at least three flares of gout during the previous year, had discontinued urate-lowering therapy and colchicine, and had a serum uric acid level of 7.5 to 12 mg/dL.

The researchers observed a 46 percent decrease in flare incidence in the 800 mg arhalofenate group versus the 300 mg allopurinol group (P = 0.0056); 800 mg arhalofenate was also significantly better than placebo (P = 0.049). However, 800 mg arhalofenate was not significantly different from treatment with 300 mg allopurinol plus 0.6 mg colchicine (P = 0.091). Mean changes in serum uric acid level were −12.5 percent with 600 mg arhalofenate and −16.5 percent with 800 mg arhalofenate (P = 0.001 and 0.0001, respectively), compared to −0.9 percent with placebo. The groups showed no meaningful differences in adverse events between groups, and there were no serious adverse events tied to arhalofenate.

"Arhalofenate is the first urate-lowering antiflare therapy," the authors write.

Several authors disclosed financial ties to CymaBay Therapeutics, which manufactures arhalofenate and funded the study.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »